Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claudia Piccinini
Observed names:
C. Piccinini,
Piccinini, Claudia
Institution:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Observed institution:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
ORCID:
0000-0001-5862-6207
Observed ORCID:
0000-0001-5862-6207
OpenAlex ID:
A5067537551
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
2024
·
Paolo A. Ascierto
, Milena Casula
, et al.
·
Nature Communications
·
111
PDF
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
2021
·
Jenny Bulgarelli
, Claudia Piccinini
, et al.
·
Frontiers in Immunology
·
26
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
2024
·
Paolo A. Ascierto
, Mario Mandalà
, et al.
·
NEJM Evidence
·
21
PDF
In vitro CAR-T cell killing: validation of the potency assay
2024
·
Claudia Piccinini
, Silvia Carloni
, et al.
·
Cancer Immunology Immunotherapy
·
13
PDF
Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial
2025
·
Jenny Bulgarelli
, Claudia Piccinini
, et al.
·
Journal of Translational Medicine
·
9
PDF
Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products
2024
·
Anna Maria Granato
, Elena Pancisi
, et al.
·
Cytotherapy
·
8
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center
2022
·
Elena Pancisi
, Anna Maria Granato
, et al.
·
Vaccines
·
8
PDF
Potency Assessment of Dendritic Cell Anticancer Vaccine: Validation of the Co-Flow DC Assay
2021
·
Silvia Carloni
, Claudia Piccinini
, et al.
·
International Journal of Molecular Sciences
·
7
PDF
Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial.
2025
·
Hildur Helgadottir
, Mariaelena Capone
, et al.
·
Journal of Clinical Oncology
·
2
397 Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2025
·
Marcella Tazzari
, Silvia Carloni
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
1
159P Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
2024
·
G.N. Sabatino
, D. Fanelli
, et al.
·
Immuno-Oncology Technology
·
1
PDF
49P A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results
2021
·
L. Ridolfi
, J. Bulgarelli
, et al.
·
Annals of Oncology
·
1
Development and validation of the IFN-γ FlowCytoScreen for cytokine-based potency assessment of advanced therapy medicinal products
2026
·
Silvia Carloni
, Claudia Piccinini
, et al.
·
Frontiers in Immunology
PDF
Additional file 1 of Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2026
·
Tazzari, Marcella
, Carloni, Silvia
, et al.
·
Figshare
Additional file 2 of Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2026
·
Tazzari, Marcella
, Carloni, Silvia
, et al.
·
Figshare
Additional file 4 of Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2026
·
Tazzari, Marcella
, Carloni, Silvia
, et al.
·
Figshare
Additional file 5 of Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2026
·
Tazzari, Marcella
, Carloni, Silvia
, et al.
·
Figshare
Additional file 7 of Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2026
·
Tazzari, Marcella
, Carloni, Silvia
, et al.
·
Figshare
Additional file 3 of Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2026
·
Tazzari, Marcella
, Carloni, Silvia
, et al.
·
Figshare
Additional file 6 of Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma
2026
·
Tazzari, Marcella
, Carloni, Silvia
, et al.
·
Figshare
83P Immunomonitoring of dendritic cell-based vaccination post-metastasectomy in colorectal cancer: Preliminary findings from the phase II COREVAX-1 trial
2025
·
F.G. Sullo
, J. Bulgarelli
, et al.
·
Immuno-Oncology Technology
PDF
528 A novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution identified predictive spatial biomarkers in immunotherapy- and targeted therapy-treated melanoma patients
2025
·
Antonio Sorrentino
, Ettai Markovits
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for predictive spatial biomarker identification on immunotherapy-treated melanoma patients.
2025
·
Paolo Antonio Ascierto
, Marion Bonnet
, et al.
·
Journal of Clinical Oncology
PDF
Dynamic Immune Modulation by Dendritic Cell Vaccination and IFN-α in Advanced Melanoma: Final Insights from the ABSIDE Phase II Trial
2025
·
Jenny Bulgarelli
, Giada N. Sabatino
, et al.
·
Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)
49P Exploiting multi-omic integrated data from DC-vaccinated melanoma patients for the generation of an advanced adoptive T cell therapy
2022
·
J. Bulgarelli
, M. Tazzari
, et al.
·
Immuno-Oncology Technology
Show more works
View as search
Works count:
35
Citation count:
208
H-index:
7
I10-index:
4
Year
Topic
Type